Why Falling Membership Could Be the Turning Point for Centene

Hook & thesis

Centene (CNC) has been punished for shrinking membership: total membership slipped from 27.9 million to 26.27 million year-over-year and ACA marketplace membership plunged from 5.626 million to 3.582 million as pandemic-era subsidies expired. The market read that as secular deterioration. I think that reading is incomplete. What the market may be underappreciating is that Centene is choosing margin over low-margin top line growth, and that decision happens to pair with a very attractive valuation and a Medicare payment environment that is turning more favorable.

We are proposing a tactical long: enter now at $64.49, stop at $58.00, and target $75.00 over a mid-term horizon (45 trading days). The combination of margin-driven profitability improvements, meaningful free cash flow ($8.951 billion per the latest ratios), and an EV/EBITDA of ~5.23 implies a lower-risk asymmetric setup versus peers and its own history.

Business primer - what Centene does and why the market should care

Centene is a government-focused managed care operator with four segments: Medicaid, Medicare, Commercial, and Other (pharmacy, vision/dental, behavioral health and related services). Medicaid remains the largest part of the book; recent data show Medicaid membership falling to ~12.52 million from 13.00 million. The ACA marketplace book was hit hardest when enhanced subsidies ended, which explains a headline membership slump.

Why care? Centene's profit engine depends on two levers: membership scale and margins per member. Scale matters for pharmacy negotiating power, care management infrastructure and administrative leverage. But margins per member drive cash conversion and free cash flow. Management recently signaled a deliberate choice to favor margin over marginally profitable members, and that shift can lift earnings and cash flow even with lower member counts.

Data points that matter

• Membership: Total membership dropped from 27.9M to 26.27M year-over-year; ACA marketplace membership down from 5.626M to 3.582M (06/16/2026 report).
• Revenue & guidance: Centene reported Q4 2025 revenue of $49.73B (beat) but the stock reacted poorly to a cautious 2026 outlook; management expected adjusted EPS north of $3.00 for 2026 in commentary tied to margin focus.
• Valuation: Market cap is roughly $33.3B (snapshot) with enterprise value about $23.67B, EV/EBITDA ~5.23, P/FCF ~3.54 and price-to-sales ~0.16. Free cash flow is reported at ~$8.951B.
• Balance sheet & liquidity: Debt-to-equity around 0.71, current ratio ~2.34, and cash on the balance sheet expressed in ratios at ~1.29 (units per dataset metric).
• Price action and technicals: 52-week high $69.36, 52-week low $25.08; current price $64.49 sits near the 20- and 50-day SMAs (SMA50 $64.15, SMA20 $64.98), and RSI ~49.9 indicates a neutral momentum backdrop.

Why declining membership can be constructive

There are three practical ways lower membership can improve Centene's earnings profile:

• Elimination of low-margin members - marketplace and other non-core members tend to carry lower margins and higher churn. Management has signaled prioritizing margin versus membership growth; shedding low-profit members can quickly lift the health benefits ratio and operating margins.
• Improved risk pools and risk score clarity - CMS maintained the 2024 risk adjustment model and then revised capitation assumptions higher for 2027; a 2.48% bump in Medicare Advantage capitation rates (announced 04/07/2026) translates into better expected unit economics in the Medicare book, where Centene can scale premium dollars with less incremental capital.
• Cash generation over top-line growth - with reported free cash flow near $8.95B and P/FCF around 3.54, stronger margins convert materially to free cash that can be used to de-lever, buy back shares, or reinvest in higher-return initiatives like behavioral health or transportation services where Centene has scale advantages.

Valuation framing

At a market capitalization near $33.3B and enterprise value roughly $23.67B, Centene trades at EV/EBITDA ~5.23 and P/FCF ~3.54. Those are historically low multiples for a company with government-contracted revenue streams and predictable enrollment tailwinds in Medicare. The precipitous drop from a 52-week high of $69.36 down near the mid-$60s priced in significant execution risk. But the balance sheet metrics are reasonable - debt-to-equity ~0.71 and current ratio ~2.34 - which reduces bankruptcy or liquidity fears. If management can stabilize membership mix and sustain a health benefits ratio improvement toward mid-90s (previous quarter showed a high health benefits ratio of 94.3 in one report), upside to both EPS and free cash flow is credible.

Catalysts to watch (2-5)

• Medicare rate clarity and CMS decisions - any incremental improvements to MA capitation rates or risk adjustment methodology will be positive; the 04/07/2026 adjustment already helps the narrative.
• Quarterly margin improvement - sequential improvement in the reported health benefits ratio and SG&A as a percent of revenue will validate the margin-first strategy.
• Membership stabilization in Medicaid - smaller declines or stabilizing membership in Medicaid (currently ~12.52M) would remove a big overhang.
• Cash deployment announcements - debt paydown, opportunistic buybacks, or M&A focused on higher-margin assets (behavioral, pharmacy services, transportation) would re-rate the multiple.

Trade plan (actionable)

Trade stance: Long Centene (ticker: CNC)

Entry price: $64.49

Stop loss: $58.00

Target price: $75.00

Time horizon: mid term (45 trading days) - I expect the market to price in margin clarity or a constructive CMS update within this window and for headline membership concerns to be digested. If management reports improving health benefits ratio and guidance that implies EPS > $3.00, the stock should re-rate toward the $75 area given the cheap cash-flow multiples.

Sizing & risk: Treat this as a tactical swing trade. Given the volatility and headline risk around membership, limit initial size to a portion of your healthcare/allocation bucket and use the $58 stop to control downside. The stop sits below recent consolidation and gives room for normal post-earnings swings while protecting against a deeper re-rating if membership erosion accelerates.

Risks and counterarguments

Below are material risks that could invalidate the thesis, followed by a key counterargument.

• Membership erosion continues or accelerates - further large declines in Medicaid or marketplace membership would reduce revenue and could negate margin gains if fixed costs don't come down proportionally.
• Health benefits ratio remains elevated - if Centene cannot reduce the health benefits ratio from recent highs (reported at 94.3 in a prior quarter), margin expansion will be limited and EPS upside muted.
• Regulatory headwinds - unfavorable CMS decisions, caps on reimbursement, or retroactive rate adjustments could harm revenue per member and force reserve builds.
• Reputational or operational shocks - care delivery problems, provider disputes, or pharmacy reimbursement shocks could force increased claims and higher reserves.
• Macroeconomic or policy surprises - changes to federal healthcare funding, large-scale state-level Medicaid cuts, or changes to eligibility rules could materially affect enrollment and unit economics.

Counterargument - The core bearish case is straightforward: membership scale is the moat for managed-care operators. Losing members reduces negotiating leverage with PBMs, providers and the ability to spread fixed administrative costs. If Centene is forced into a long period of sub-scale membership, margins could deteriorate rather than improve, and the current cheap multiples could reflect a structurally smaller franchise.

What would change my mind

I would exit the trade and reassess if any of the following occur: a) membership declines accelerate materially beyond the levels already public (e.g., another million+ decline in two quarters), b) management abandons margin guidance and signals double-digit deterioration in the health benefits ratio, c) a negative CMS policy shift reduces MA or Medicaid reimbursement materially, or d) the company takes on material incremental debt or dilutive equity that jeopardizes cash-flow per share upside.

Conclusion

Centene's membership slump is headline-grabbing, but it may be a feature rather than a fatal flaw. Management's margin-first approach, the company's strong free cash flow (~$8.95B) and very cheap multiples (EV/EBITDA ~5.23, P/FCF ~3.54) create an asymmetry where a modest recovery or stabilization can produce outsized upside. The trade is a tactical mid-term long: enter at $64.49, stop at $58.00 and target $75.00 over ~45 trading days. Keep position size modest, watch CMS and margin metrics closely, and be prepared to cut losses if membership deterioration re-accelerates.

Key data snapshot